Update on the optimal use of bortezomib in the treatment of multiple myeloma by Mohan M, Matin A, Davies FE

Get full text

B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci by Boyle EM, Walker BA, Wardell CP, Leleu X, Davies FE, Morgan GJ

Get full text

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysi... by Lee, HC, Ramasamy, K, Macro, M, Davies, FE, Abonour, R, van Rhee, F, Hungria, VTM, Puig, N, Ren, K, Silar, J, Enwemadu, V, Cherepanov, D, Leleu, X

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients by Shah, V, Sherborne, AL, Johnson, DC, Ellis, S, Price, A, Chowdhury, F, Kendall, J, Jenner, MW, Drayson, MT, Owen, RG, Gregory, WM, Morgan, GJ, Davies, FE, Cook, G, Cairns, DA, Houlston, RS, Jackson, G, Kaiser, MF, NCRI Haematology Clinical Studies Group